Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inherited Basaloid Neoplasms Associated With SUFU Pathogenic Variants.
Abbott JJ, Jiang AJ, Godse R, Ahmed S, Senft SC, Wilson MA, Cohen JV, Mitchell TC, Ogunleye TA, Higgins HW 2nd, Shin TM, Miller CJ, Roth JJ, Priore SF, Castelo-Soccio L, Elenitsas R, Seykora JT, Nathanson KL, Chu EY. Abbott JJ, et al. Among authors: mitchell tc. JAMA Dermatol. 2024 Nov 1;160(11):1220-1224. doi: 10.1001/jamadermatol.2024.3315. JAMA Dermatol. 2024. PMID: 39292485
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival.
Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X. Ma KL, et al. Among authors: mitchell tc. Clin Cancer Res. 2024 Nov 1;30(21):4987-4994. doi: 10.1158/1078-0432.CCR-23-3775. Clin Cancer Res. 2024. PMID: 39248505
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC. Wang K, et al. Among authors: mitchell tc. Cancer Cell. 2024 Sep 9;42(9):1582-1597.e10. doi: 10.1016/j.ccell.2024.08.007. Epub 2024 Aug 29. Cancer Cell. 2024. PMID: 39214097
Anti-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of TRPM1-associated congenital stationary night blindness.
Cohen DC, Sumaroka A, Paulos JA, Mitchell TC, Santos AJ, O'Neil EC, Bedoukian EC, Adamus G, Cideciyan AV, Aleman TS. Cohen DC, et al. Among authors: mitchell tc. Am J Ophthalmol Case Rep. 2024 Jul 5;36:102098. doi: 10.1016/j.ajoc.2024.102098. eCollection 2024 Dec. Am J Ophthalmol Case Rep. 2024. PMID: 39109318 Free PMC article.
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: mitchell tc. Ann Oncol. 2024 Aug;35(8):756. doi: 10.1016/j.annonc.2024.03.002. Epub 2024 Apr 13. Ann Oncol. 2024. PMID: 38614876 Free PMC article. No abstract available.
120 results